

We claim:

1. An isolated monoclonal antibody, which binds to human glucocorticoid-inducible TNF receptor (GITR), comprising heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 23, 24, and 25, respectively.
2. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 14.
3. The antibody of claim 1 or claim 2, wherein the antibody stimulates an antigen-specific T cell response.
4. The antibody of any one of claims 1-3, wherein the antibody binds to membrane bound human GITR with a K_D of 1 nM or less as measured by Scatchard analysis.
5. The antibody of any one of claims 1-4, wherein the antibody binds to PTGGPGCGPGRLLLGTGT (SEQ ID NO: 217) and CRDYPGEE (SEQ ID NO: 218) of mature human GITR (SEQ ID NO: 4), as determined by HDX-MS.
6. The antibody of claim 1, wherein the antibody comprises heavy and light chain sequences comprising the amino acid sequences set forth in SEQ ID NOs: 15 and 16, respectively.
7. The antibody of claim 1, wherein the antibody comprises heavy and light chain sequences comprising the amino acid sequences set forth in SEQ ID NOs: 17 and 19, respectively.
8. The antibody of claim 1, wherein the antibody comprises heavy and light chain sequences comprising the amino acid sequences set forth in SEQ ID NOs: 18 and 19, respectively.
9. The antibody of any one of the claims 1-5, wherein the antibody is an IgG1, an IgG2, or an IgG4 antibody.

10. The antibody of any one of claims 1-9, wherein the antibody is a human or humanized antibody.
11. A nucleic acid encoding the heavy and light chain, or variable regions thereof, of the antibody of any one of claims 1-10.
12. An expression vector comprising the nucleic acid molecule of claim 11.
13. An isolated host cell transformed with (i) an expression vector of claim 12 or (ii) an expression vector comprising a nucleic acid encoding the heavy chain of the antibody of any one of claims 1-10 and a separate expression vector comprising a nucleic acid encoding the light chain of the antibody of any one of claims 1-10.
14. A composition comprising the antibody of any one of claims 1-10, and a carrier.
15. The composition of claim 14, further comprising one or more additional therapeutics.
16. The composition of claim 15, wherein the one or more additional therapeutics are selected from the group consisting of: an anti-PD1 antibody, an anti-LAG-3 antibody, an anti-CTLA-4 antibody, an anti-PD-L1 antibody, and combinations thereof.
17. The antibody of any one of claims 1-10 for use in treating cancer.
18. The antibody for the use in claim 17, wherein one or more additional therapeutics are to be administered.
19. The antibody for the use in claim 18, wherein the additional therapeutic is an anti-PD1 antibody, an anti-LAG-3 antibody, an anti-CTLA-4 antibody, or an anti-PD-L1 antibody.
20. The antibody of any one of claims 1-10 for use in therapy.

21. Use of the antibody of any one of claims 1-10 in the manufacture of a medicament for treating cancer.
22. The use of claim 21, wherein one or more additional therapeutics are to be administered.
23. The use of claim 22, wherein the additional therapeutic is an anti-PD1 antibody, an anti-LAG-3 antibody, an anti-CTLA-4 antibody, or an anti-PD-L1 antibody.